{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:11:51Z","timestamp":1792685511665,"version":"4.5.0"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA251374"],"award-info":[{"award-number":["R01CA251374"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA267101"],"award-info":[{"award-number":["R01CA267101"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R42CA275622"],"award-info":[{"award-number":["R42CA275622"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.drup.2026.101353","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:11:52Z","timestamp":1767715912000},"page":"101353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Mechanisms of resistance to antibody-drug conjugates in breast cancer"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7372-7812","authenticated-orcid":false,"given":"Baris","family":"Cerci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozge","family":"Saatci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Basik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8033-7089","authenticated-orcid":false,"given":"Ozgur","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101353_bib1","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-3888","article-title":"Abstract 3888: TOP1 mutations mediate cross resistance to ADCs in metastatic breast cancer","volume":"84","author":"Abelman","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.511","article-title":"A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG\/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial","volume":"43","author":"Abelman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib3","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 Mutations and Cross-Resistance to Antibody\u2013Drug Conjugates in Patients with Metastatic Breast Cancer","author":"Abelman","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib4","article-title":"Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","author":"Alaklabi","year":"2024","journal-title":"JCO Oncol. Pr."},{"key":"10.1016\/j.drup.2026.101353_bib5","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-1711","article-title":"Abstract 1711: Genomic and transcriptomic mediators of resistance to antibody-drug conjugates (ADCs) in metastatic breast cancer (MBC): A comprehensive multi-center study","volume":"85","author":"Alkassis","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.1041","article-title":"Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study","volume":"43","author":"Alkassis","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104163","article-title":"7O Trastuzumab deruxtecan (T-DXd) \u00b1 pertuzumab (P) in previously untreated HER2+ metastatic breast cancer (mBC): Clinical efficacy and exploratory subgroup analyses in DESTINY-Breast07","volume":"10","author":"Andr\u00e9","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.drup.2026.101353_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.3025","article-title":"Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced\/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC)","volume":"40","author":"Andre","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101353_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.607","article-title":"Role of tumor infiltrating lymphocytes (TILs) in HER2+ metastatic breast cancers (MBC) treated with trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C) (EMILIA Trial)","volume":"34","author":"Badve","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib11","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1126\/sciadv.abh1004","article-title":"PLK1 regulates the PrimPol damage tolerance pathway during the cell cycle","volume":"7","author":"Bailey","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2026.101353_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-017-0900-z","article-title":"Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers","volume":"19","author":"Baldassarre","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor\u2013Positive Human Epidermal Growth Factor Receptor 2\u2013Negative Breast Cancer: Primary Results From TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib14","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib15","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1\/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2868","article-title":"Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo","volume":"13","author":"Barok","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib18","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101353_bib19","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-15-2499","article-title":"Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-Positive metastatic breast cancer","volume":"22","author":"Baselga","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib20","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-25-A040","article-title":"Abstract A040: Resistance to trastuzumab deruxtecan acquired through multifaceted pathway alterations in preclinical models","volume":"24","author":"Bhavsar","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101353_bib21","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-24-2449","article-title":"XMT-2056, a HER2-Directed STING Agonist Antibody\u2013Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells","volume":"31","author":"Bukhalid","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) -positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib23","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/1541-7786.MCR-21-0545","article-title":"mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer","volume":"20","author":"Casadevall","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib24","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1016\/j.annonc.2023.09.2830","article-title":"375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors","volume":"34","author":"Cavalcante","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib25","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO4-14-10","article-title":"Abstract PO4-14-10: Circulating Tumor DNA as a Biomarker for ADCs in Metastatic Breast Cancer","volume":"84","author":"Chang","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2026.101353_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185408","article-title":"68Ga-MY6349 PET\/CT imaging to assess Trop2 expression in multiple types of cancer","volume":"135","author":"Chen","year":"2025","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2026.101353_bib28","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1093\/oncolo\/oyae055","article-title":"Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance","volume":"29","author":"Chen","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.drup.2026.101353_bib29","article-title":"Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding","author":"Chen","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101353_bib30","article-title":"SNX10 deficiency impairs sensitivity to anti-HER2 antibody\u2013drug conjugates via altering HER2 trafficking in HER2-positive breast cancer","volume":"122","author":"Chen","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101353_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/17425255.2024.2302460","article-title":"Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer","volume":"20","author":"Cherifi","year":"2024","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.drup.2026.101353_bib32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101353_bib33","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101353_bib34","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of Antibody\u2013Drug Conjugates: Lessons Learned from 40 Years of Development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101353_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","author":"Cort\u00e9s","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101353_bib36","article-title":"Site-Specific Immune and Stromal Architecture Drive Resistance to Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer","author":"Das","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.drup.2026.101353_bib37","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-022-01587-z","article-title":"Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine\u2009+\u2009pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)","author":"de Haas","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib38","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1158\/1078-0432.CCR-22-1989","article-title":"Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer","volume":"29","author":"Denkert","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib39","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib40","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-23-0103","article-title":"Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers","volume":"29","author":"DiPeri","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400109","article-title":"The Evolution of Antibody-Drug Conjugates: Toward Accurate DAR and Multi-specificity","author":"Dong","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drup.2026.101353_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.1052","article-title":"HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers","volume":"41","author":"Drago","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.1028","article-title":"JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies","volume":"43","author":"Du","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib44","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2026.101353_bib45","article-title":"NF1 modulates microtubule repair and sensitivity to antibody-drug conjugates","author":"Duso","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.drup.2026.101353_bib46","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-26018-z","article-title":"RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer","volume":"12","author":"Engebraaten","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101353_bib48","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-OT1-22-01","article-title":"Abstract OT1-22-01: Liquid biopsy and Ado-trastuzumab emtansine (T-DM1): drug-resistance traits in the blood of HER2-positive metastatic breast cancer patients","volume":"83","author":"Fabi","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41417-023-00701-3","article-title":"The target atlas for antibody-drug conjugates across solid cancers","volume":"31","author":"Fang","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.drup.2026.101353_bib50","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of her2 heterogeneity on treatment response of early-stage her2-positive breast cancer: Phase ii neoadjuvant clinical trial of t-dm1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101353_bib51","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody\u2013drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2026.101353_bib52","doi-asserted-by":"crossref","DOI":"10.21037\/acr-2025-118","article-title":"ErbB signaling and cell cycle pathways associated with trastuzumab deruxtecan resistance in HER2-positive metastatic breast cancer: a case report","volume":"9","author":"Gao","year":"2025","journal-title":"AME Case Rep."},{"key":"10.1016\/j.drup.2026.101353_bib53","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1038\/onc.2013.202","article-title":"An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer","volume":"33","author":"Garcia-Murillas","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101353_bib54","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-23-2812","article-title":"Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer","volume":"84","author":"Gedik","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.drup.2026.101353_bib56","article-title":"Breast cancer statistics 2024","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2026.101353_bib57","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101353_bib58","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/jnci\/djv222","article-title":"The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene","volume":"107","author":"Gottesman","year":"2015","journal-title":"JNCI Journal National Cancer Institute"},{"key":"10.1016\/j.drup.2026.101353_bib59","first-page":"OF1","article-title":"Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer","author":"Gouda","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib60","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2322688121","article-title":"Cancer\u2013stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies","volume":"121","author":"Goyette","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101353_bib61","first-page":"1942","article-title":"Alternative splicing generates HER2 isoform diversity underlying antibody\u2013drug conjugate resistance in breast cancer","volume":"35","author":"Guardia","year":"2025","journal-title":"Genome Res"},{"key":"10.1016\/j.drup.2026.101353_bib62","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/cancers15041130","article-title":"Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges","volume":"15","author":"Guidi","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101353_bib63","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM10-618","article-title":"Abstract 618: Role of multidrug resistance transporters in the biological response to trastuzumab-cytotoxic drug conjugates","volume":"70","author":"Guo","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib64","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41588-025-02187-1","article-title":"APOBEC3 mutagenesis drives therapy resistance in breast cancer","volume":"57","author":"Gupta","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drup.2026.101353_bib65","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/0008-5472.CAN-15-1610","article-title":"SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm","volume":"75","author":"Hamblett","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib66","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib67","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-1457","article-title":"Abstract 1457: Genomic characterization of a PDX model of T-DM1-resistant HER2+ invasive ductal carcinoma using augmented exome sequencing","volume":"75","author":"Helman","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib68","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3390\/cancers15102664","article-title":"HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept","volume":"15","author":"Hou","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101353_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-025-00748-5","article-title":"Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)","volume":"11","author":"Huppert","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.drup.2026.101353_bib70","doi-asserted-by":"crossref","first-page":"GS01-10","DOI":"10.1158\/1538-7445.SABCS23-GS01-10","article-title":"Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer","volume":"84","author":"Hurvitz","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-025-02701-8","article-title":"A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a multicenter cohort study","volume":"11","author":"Islam","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.drup.2026.101353_bib72","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101353_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241309461","article-title":"Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy","volume":"17","author":"Izzo","year":"2025","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib74","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-PS8-03","article-title":"Abstract PS8-03: Exploratory biomarker analysis of Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2\u2013positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03)","volume":"31","author":"Jacot","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib75","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-018-4792-0","article-title":"Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy","volume":"171","author":"Jain","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.drup.2026.101353_bib76","article-title":"The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2-positive breast cancer","volume":"6","author":"Janiszewska","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.drup.2026.101353_bib77","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-1701","article-title":"Abstract 1701: Investigating trastuzumab-deruxtecan (DS-8201) resistance mechanisms using clinically relevant PDX models and combination strategies with anti-PD-1 antibody","volume":"85","author":"Jiang","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.drup.2026.101353_bib79","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41557-024-01507-y","article-title":"Homogeneous multi-payload antibody\u2013drug conjugates","volume":"16","author":"Journeaux","year":"2024","journal-title":"Nat. Chem."},{"key":"10.1016\/j.drup.2026.101353_bib80","doi-asserted-by":"crossref","first-page":"8626","DOI":"10.1126\/sciadv.abb8626","article-title":"The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment","volume":"6","author":"Juh\u00e1sz","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2026.101353_bib81","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/ijc.30276","article-title":"Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician\u2019s choice in previously treated HER2-positive advanced breast cancer","volume":"139","author":"Kim","year":"2016","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.drup.2026.101353_bib82","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","article-title":"SLC46A3 as a potential predictive biomarker for antibody\u2013drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads","volume":"24","author":"Kinneer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib83","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.21.00896","article-title":"Trastuzumab Emtansine plus Pertuzumab Versus Taxane plus Trastuzumab plus Pertuzumab after Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study","volume":"40","author":"Krop","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib84","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1074\/jbc.M403080200","article-title":"Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling","volume":"280","author":"Le","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2026.101353_bib85","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-23-B041","article-title":"Abstract B041: A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation","volume":"22","author":"Lee","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101353_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-024-03143-3","article-title":"The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody\u2013drug conjugate\u2013resistant HER2-overexpressing breast cancer","volume":"43","author":"Lee","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib87","first-page":"S263","article-title":"145P Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1","volume":"36","author":"Lee","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500262","article-title":"Linker Design for The Antibody Drug Conjugates: A Comprehensive Review","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drup.2026.101353_bib89","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody\u2013Cytotoxic Drug Conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib90","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101353_bib91","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41419-024-06838-9","article-title":"SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR\u2009+\u2009HER2\u2212 breast cancer","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2026.101353_bib92","article-title":"First-in-human, phase I study of CBP-1008, a first-in-class bispecific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib93","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody\u2013drug conjugates: A review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drup.2026.101353_bib94","article-title":"HER2 heterogeneity and treatment response\u2013associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.drup.2026.101353_bib95","doi-asserted-by":"crossref","first-page":"iii22","DOI":"10.1093\/annonc\/mdz095.067","article-title":"Functional CRISPR knockout screens for modifiers of sensitivity to trastuzumab emtansine","volume":"30","author":"Lipert","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib96","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101353_bib97","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(18)30812-X","article-title":"Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b\u20132 trial","volume":"20","author":"Loi","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib98","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","article-title":"Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules","volume":"9","author":"Lopus","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101353_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116233","article-title":"Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates","volume":"268","author":"Lu","year":"2024","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.drup.2026.101353_bib100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.drup.2026.101353_bib101","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00898","article-title":"Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan","author":"Mai","year":"2025","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib102","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.1045","article-title":"Effect of ERBB2 activating mutations on enhanced internalization and activity of trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer","volume":"43","author":"Mai","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib103","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P1-02-28","article-title":"Abstract P1-02-28: PDGFRa+\/FAP- fibroblasts at multiplex in situ resolution are associated with resistance to HER2 blockade in neoadjuvant treated HER2+ breast cancer: results from the Swedish PREDIX HER2 trial","volume":"31","author":"Manikis","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114699","article-title":"178 (PB166): Patient-derived models of ER+ HER2 - metastatic breast cancers reveal KRAS-MAPK signalling pathway as therapeutic target for overcoming resistance to trastuzumab-deruxtecan","volume":"211","author":"Marangoni","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drup.2026.101353_bib105","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251332473","article-title":"The mechanisms of HER2 targeted ADCs are dependent on Rab GTPases","volume":"17","author":"Medhus","year":"2025","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib106","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/1078-0432.CCR-16-0970","article-title":"TNF\u03b1-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer","volume":"23","author":"Mercogliano","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib107","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1158\/1078-0432.CCR-24-1948","article-title":"Antitumor Activity and Biomarker Analysis for TROP2 Antibody\u2013Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models","volume":"31","author":"Meric-Bernstam","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib108","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.502","article-title":"HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial","volume":"37","author":"Metzger Filho","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-023-00610-6","article-title":"Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)","volume":"10","author":"Mileva","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.drup.2026.101353_bib110","article-title":"Epitope Expression Persists in Circulating Tumor Cells as Breast Cancers Acquire Resistance to Antibody Drug Conjugates","author":"Mishra","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.drup.2026.101353_bib111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101353_bib112","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.1020","article-title":"Trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and\/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04","volume":"41","author":"Modi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib113","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101353_bib114","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med"},{"key":"10.1016\/j.drup.2026.101353_bib115","doi-asserted-by":"crossref","first-page":"S359","DOI":"10.1016\/j.annonc.2024.08.291","article-title":"343MO Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib116","first-page":"7","article-title":"Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade","author":"M\u00fcller","year":"2015","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.drup.2026.101353_bib117","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.molcel.2018.01.012","article-title":"SLFN11 Blocks Stressed Replication Forks Independently of ATR","volume":"69","author":"Murai","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.drup.2026.101353_bib118","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3390\/cancers12030670","article-title":"The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1","volume":"12","author":"Nadal-Serrano","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101353_bib119","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS509","volume":"43","author":"Nakayama","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib120","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-5857","article-title":"Abstract 5857: Trastuzumab deruxtecan resistance can be mediated by payload resistance or secondary extracellular ERBB2 mutations but sensitivity to HER2 tyrosine kinase inhibitors is maintained","volume":"84","author":"Nilsson","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib121","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib122","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4097","article-title":"Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): Exploratory results from the HERB trial","volume":"41","author":"Ohba","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib123","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101353_bib124","article-title":"Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC)","volume":"43","author":"O\u2019Meara","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib125","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1158\/1535-7163.MCT-10-0645","article-title":"Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability","volume":"9","author":"Oroudjev","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101353_bib126","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41392-025-02409-2","article-title":"Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02)","volume":"10","author":"Pan","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101353_bib127","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.drup.2026.101353_bib128","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","article-title":"The Therapeutic Effect of Anti-HER2\/neu Antibody Depends on Both Innate and Adaptive Immunity","volume":"18","author":"Park","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101353_bib129","article-title":"Phase ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: Stela results","volume":"36","author":"Patel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib130","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-4353","article-title":"Abstract 4353: Utilizing scRNA sequencing to understand biomarkers of response and resistance to Sacitizumab Govetican in localized TNBC","volume":"83","author":"Peiris","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib131","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.annonc.2024.04.002","article-title":"Antibody\u2013drug conjugates in lung and breast cancer: current evidence and future directions\u2014a position statement from the ETOP IBCSG Partners Foundation","volume":"35","author":"Peters","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib132","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P1-13-03","article-title":"Abstract P1-13-03: Establishment and characterization of two T-DM1-resistant, ER+\/HER2+ breast XPDX models developed sequentially from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)","volume":"83","author":"Plasko","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib133","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101353_bib134","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1078-0432.CCR-22-3640","article-title":"New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads","volume":"29","author":"Pommier","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib135","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-LB227","article-title":"Abstract LB227: Leveraging novel Dato-DXd resistance models to inform biomarker discovery and rational combinations to combat drug resistance","volume":"83","author":"Przybyla","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib136","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-25-A041","article-title":"Abstract A041: Emergence of TOP1 mutations as a potential biomarker of resistance to topoisomerase-targeting regimens","volume":"24","author":"Reddy","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drup.2026.101353_bib137","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody\u2013drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib138","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"Rubahamya","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2026.101353_bib139","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101353_bib140","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P5-07-29","article-title":"Abstract P5-07-29: Trastuzumab deruxtecan With Pembrolizumab in Previously Treated HER2-Expressing Advanced or Metastatic Breast Cancer: Interim Analyses of the Breast Cohorts from the Open-Label, Multicenter, Phase 1b Study DS8201-A-U106","volume":"31","author":"Rugo","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib141","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41388-017-0108-9","article-title":"Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2\/xL in HER2-positive breast cancer","volume":"37","author":"Saatci","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101353_bib142","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","article-title":"Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies","volume":"99","author":"Saatci","year":"2021","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.drup.2026.101353_bib143","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1158\/1078-0432.CCR-17-0696","article-title":"Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer","volume":"23","author":"Sabbaghi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib144","doi-asserted-by":"crossref","first-page":"TPS4180","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4180","article-title":"A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors","volume":"42","author":"Sands","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib145","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-1103","article-title":"Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?","volume":"9","author":"Santi","year":"2021","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.drup.2026.101353_bib146","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-309","article-title":"Abstract 309: Mechanisms of resistance to trastuzumab emtansine in gastric cancer","volume":"76","author":"Sauveur","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib147","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1073\/pnas.1014835108","article-title":"Cyclin E amplification\/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients","volume":"108","author":"Scaltriti","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.drup.2026.101353_bib148","volume":"9","author":"Schmid","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.drup.2026.101353_bib149","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx065","article-title":"An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression","volume":"109","author":"Schwarz","year":"2017","journal-title":"JNCI Journal National Cancer Institute"},{"key":"10.1016\/j.drup.2026.101353_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100299","article-title":"HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer","volume":"36","author":"Shen","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.drup.2026.101353_bib151","doi-asserted-by":"crossref","first-page":"PS13-09","DOI":"10.1158\/1557-3265.SABCS24-PS13-09","article-title":"Abstract PS13-09: Mechanisms of Resistance to Trastuzumab Deruxtecan in Breast Cancer Elucidated by Multi-omic Molecular Profiling","volume":"31","author":"Sledge","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib152","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.PRCA2023-B016","article-title":"Abstract B016: Liquid biopsy biomarker analysis of a phase II trial of sacituzumab govitecan in castrate resistant metastatic prostate cancer","volume":"83","author":"Sperger","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib153","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","article-title":"Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial","volume":"35","author":"Spring","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib154","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.ADVBC23-PR08","article-title":"Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized TNBC","volume":"84","author":"Spring","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib155","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P4-08-06","article-title":"Abstract P4-08-06: Onvansertib enhances the anti-tumor efficacy of trastuzumab deruxtecan in CDK4\/6 inhibitor-resistant HR+\/HER2- breast cancer patient-derived xenograft models","volume":"31","author":"Sreekumar","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib156","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-7268","article-title":"Abstract 7268: A novel immunocompetent tumor model reveals the immunomodulatory effects of trastuzumab deruxtecan","volume":"85","author":"Steele","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib157","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101353_bib158","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody\u2013drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.drup.2026.101353_bib159","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.1077","article-title":"Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer","volume":"42","author":"Tarantino","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib160","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/jnci\/djaf220","article-title":"Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer","volume":"117","author":"Tarantino","year":"2025","journal-title":"JNCI Journal National Cancer Institute"},{"key":"10.1016\/j.drup.2026.101353_bib161","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/antib11040078","article-title":"Delivery of Drugs into Cancer Cells Using Antibody\u2013Drug Conjugates Based on Receptor-Mediated Endocytosis and the Enhanced Permeability and Retention Effect","volume":"11","author":"Tashima","year":"2022","journal-title":"Antibodies"},{"key":"10.1016\/j.drup.2026.101353_bib162","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-11-1417","article-title":"Antibody Conjugate Therapeutics: Challenges and Potential","volume":"17","author":"Teicher","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib163","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib164","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib165","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 quantitatively stimulates human cancer growth","volume":"32","author":"Trerotola","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101353_bib166","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155636","article-title":"Trastuzumab\/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis","volume":"7","author":"Tsao","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.drup.2026.101353_bib167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101353_bib168","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6074.TUMIMM24-A059","article-title":"Abstract A059: Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer","volume":"12","author":"Tsao","year":"2024","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.drup.2026.101353_bib169","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib170","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.1038\/onc.2016.129","article-title":"The ErbB2\u0394Ex16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment","volume":"35","author":"Turpin","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2026.101353_bib171","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.1016\/j.annonc.2024.08.379","article-title":"432P Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician\u2019s choice in HER2-low, hormone receptor\u2013positive metastatic breast cancer in DESTINY-Breast04","volume":"35","author":"Ueno","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib172","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-025-00829-5","article-title":"Antibody\u2013drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives","volume":"11","author":"Valle","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.drup.2026.101353_bib173","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118977","article-title":"A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design","volume":"10","author":"Vasalou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2026.101353_bib174","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101353_bib175","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101353_bib176","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.3390\/cancers14205115","article-title":"Resistance to Trastuzumab","volume":"14","author":"Vivekanandhan","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101353_bib177","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101353_bib178","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody\u2013drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.drup.2026.101353_bib179","article-title":"Abstract PO2-07-06: Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib180","article-title":"Abstract 7270: Novel humanized cell and murine models expressing tumor-associated antigens for ADC toxicity and IO combination evaluation","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib181","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-3449","article-title":"Abstract 3449: The role of N-terminal cleavage of Trop2 in tumor progression and therapeutic resistance in triple negative breast cancer","volume":"85","author":"Wilson","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib182","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib183","article-title":"Abstract 5858: Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer","volume":"84","author":"Wu","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib184","doi-asserted-by":"crossref","first-page":"PS08-07","DOI":"10.1158\/1538-7445.SABCS23-PS08-07","article-title":"Abstract PS08-07: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Results from a phase 1 study","volume":"84","author":"Wu","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib185","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-16-2191","article-title":"HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer","volume":"23","author":"Xu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib186","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1016\/j.jtho.2024.09.827","article-title":"EP.03E.02 Elucidation of Trastuzumab-Deruxtecan Resistance Mechanisms using in Vivo Xenograft Model Reflecting Pharmacokinetics","volume":"19","author":"Yano","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib187","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e13138","article-title":"First-in-human study of JSKN016, a bispecific anti-TROP2\/HER3 antibody drug conjugate (ADC): Antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results","volume":"43","author":"Yao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib188","article-title":"Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses","volume":"28","author":"Zhang","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.drup.2026.101353_bib189","doi-asserted-by":"crossref","first-page":"S427","DOI":"10.1016\/j.annonc.2025.10.925","article-title":"538P Preliminary efficacy and safety of TQB2102 in patients with HER2 positive recurrent\/metastatic breast cancer: Results from a phase Ib study","volume":"36","author":"Zhang","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101353_bib190","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody\u2013drug conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib191","article-title":"Abstract 1585: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model","volume":"85","author":"Zhao","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2026.101353_bib192","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1158\/1078-0432.CCR-18-1505","article-title":"Ligand-binding domain\u2013activating mutations of ESR1 rewire cellular metabolism of breast cancer cells","volume":"25","author":"Zinger","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101353_bib193","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876462600004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S136876462600004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:49:30Z","timestamp":1773953370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S136876462600004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":193,"alternative-id":["S136876462600004X"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101353","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of resistance to antibody-drug conjugates in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101353"}}